TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33106167
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care and 400 ml CP
Study: 34236768
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose enoxaparin
Study: 34236768
Drug: Standard prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylactic dose enoxaparin
Study: 35483181
Drug: Intrapersonal consequences
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapersonal consequences (e.g., sad mood)
Study: 34302120
Drug: Total Diet
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Diet Replacement (TDR) for 8 weeks, followed by food-reintroduction over 4 weeks, with weekly behavioral support for 8 weeks, bi-weekly for 4 weeks, then monthly for 3 months
Study: 32784257
Drug: PLACEBO (Sham)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO (Sham) treatment
Study: 36279266
Drug: Low Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Level Laser Therapy (LLLT), administered three times a week for 3 weeks
Study: 36279266
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave Therapy (ESWT), administered once a week for 3 weeks
Study: 34120463
Drug: Cream with
Normalized name: CREAM WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream with lipid nanoparticles and vitamin E (Group A)
Study: 34120463
Drug: Cream without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream without nanoparticles nor vitamin E (Group B)
Study: 34120463
Drug: Cream with
Normalized name: CREAM WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream with nanoparticles without vitamin E (Group C)
Study: 32993355
Drug: Diet 2
Normalized name: gluc-msm-vit C-FA-mang-diet 29 125 mg-37.5 mg-25 mg-500 mcg-1.25 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 2 (SFSe) with 12.605 mg/kg Se additive
Study: 32993355
Drug: Diet 4
Normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 4 (USFSe) with 12.605 mg/kg Se additive
Study: 32026826
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (HA+HS with oscillatory‐PEP)
Study: 34543687
Drug: Intensive BP
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive BP treatment (systolic BP <120 mm Hg)
Study: 34543687
Drug: Standard BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BP treatment (systolic BP <140 mm Hg)
Study: 34696811
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (brief counseling sessions and low-dose physical activity recommendations)
Study: 33025448
Drug: Community pharmacists'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacists' knowledge regarding malaria and its treatment
Study: 33025448
Drug: Community pharmacists'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacists' practices regarding antimalarials dispensing
Study: 33025448
Drug: Barriers to
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barriers to effective contribution in malaria prevention and treatment
Study: 35940087
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine infusion (0.5 mg/kg)
Study: 34521212
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy (CT) or Interpersonal Psychotherapy (IPT)
Study: 34027858
Drug: Intradermal platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal platelet-rich plasma (PRP) 1 ml
Study: 34027858
Drug: Intradermal tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal tranexamic acid 4 mg
Study: 36042527
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (not specified)
Study: 32358867
Drug: SUMI+ RBCs
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUMI+ RBCs examined by immunocomplex capture fluorescence analysis (ICFA) using HIRO-305 and murine monoclonal antibodies against RBC membrane proteins carrying blood group antigens.
Study: 35705380
Drug: Standard trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard trigger dose of hCG (5,000 or 10,000 IU)
Study: 35221357
Drug: Prophylactic combination
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic combination of glycopyrrolate, ondansetron, and ephedrine
Study: 35221357
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ephedrine boluses as required)
Study: 32044091
Drug: Labelling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labelling the number of doses per package
Study: 34503491
Drug: Fresh cassava
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh cassava root (300 mg of total substrate)
Study: 36226669
Drug: Tapinarof 1%
Normalized name: TAPINAROF 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapinarof 1% cream
Study: 32862716
Drug: Ticagrelor added
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor added to standard aspirin (80 mg or 100 mg)
Study: 32862716
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to standard aspirin (80 mg or 100 mg)
Study: 35426778
Drug: Oral arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral arginine supplementation
Study: 34130033
Drug: High n‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High n‐3 PUFA, average n‐6 PUFA (H3) diet targeting 1500 mg EPA+DHA/day and 7% of energy from n‐6 linoleic acid (LA)
Study: 34130033
Drug: High n‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High n‐3 PUFA, low‐n‐6 PUFA (H3L6) targeting 1500 mg EPA+DHA/day and <1.8 en% n‐6 LA
Study: 34130033
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet with typical American intakes of both EPA+DHA (<150 mg/day) and 7 en% from n‐6 LA
Study: 35115574
Drug: IV Interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Interferon (IFN) beta‐1a (10 μg) for 6 days after surgery
Study: 33479268
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon (Si) at 1 mmol L-1
Study: 33479268
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon (Si) at 3 mmol L-1
Study: 33479268
Drug: Cadmium (Cd)
Normalized name: cadmium
DrugBank: Cadmium (DB14085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadmium (Cd) at 50 µmol L-1
Study: 33479268
Drug: Cadmium (Cd)
Normalized name: cadmium
DrugBank: Cadmium (DB14085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadmium (Cd) at 200 µmol L-1
Study: 32769643
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (50 units, injected twice, 3 months apart)
Study: 32769643
Drug: Placebo (injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (injected twice, 3 months apart)
Study: 34462956
Drug: Synbiotic capsules
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic capsules (Lactobacillus, Bifidobacterium, Streptococcus, and fructooligosaccharides) twice per day for 14 days
Study: 34610580
Drug: Paroxetine/Fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine/Fluoxetine
Study: 35525480
Drug: BDP/FF 200/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF 200/12 μg via DPI
Study: 35525480
Drug: BDP/FF 400/24
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF 400/24 μg via DPI
Study: 35525480
Drug: BDP/FF 800/48
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF 800/48 μg via DPI
Study: 33879263
Drug: Amoxicillin (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (7-day course)
Study: 32954807
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin (PV) in combination with bendamustine and rituximab
Study: 34898493
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention focusing on antimicrobial agents prescribing and resistance
Study: 34280013
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 600mg over 2h (loading dose) and 1200mg over 22h (continuous group)
Study: 33564825
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention (600 kcal energy, 20 g protein, and micronutrient supplementation daily)
Study: 37401479
Drug: Inhaled Epoprostenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Epoprostenol (iEPO)
Study: 33840769
Drug: Machine-based hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Machine-based hand massage therapy (experimental group)
Study: 32520602
Drug: Indirect laryngeal
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect laryngeal biopsy forceps combined with antibiotics
Study: 32272255
Drug: Crushed prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed prasugrel tablets
Study: 32272255
Drug: Integral prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integral prasugrel tablets
Study: 32900785
Drug: Linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin (5 mg once daily for 8 weeks)
Study: 36270742
Drug: Nitisinone 10
Normalized name: nitisinone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitisinone 10 mg/day
Study: 33636616
Drug: Seasonally adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonally adjusted 25(OH)D levels below 80 nmol/L
Study: 32767414
Drug: Feru-guard 100M
Normalized name: Clinda-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feru-guard 100M (daily for 48 weeks)
Study: 36991396
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no supplement)
Study: 35357350
Drug: Routine drug
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drug treatment
Study: 35501215
Drug: 25% dextrose
Normalized name: Delflex with 4.25% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% dextrose solution
Study: 33565409
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment (30 minutes, twice daily) on Zusanli, Tianshu, Shangjuxu, Xiajuxu, and Zhongwan, in addition to conventional western medicine for 7 days.
Study: 33565409
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine treatment for 7 days.
Study: 33999414
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment - participants learned of a mood-enhancing treatment and received it
Study: 33999414
Drug: Treatment deprivation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment deprivation - participants learned of the same treatment, but did not receive it
Study: 33999414
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - treatment was never mentioned
Study: 36540062
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of 400 mg albendazole and either 9‐ or 18 mg ivermectin (single dose or three consecutive days)
Study: 36540062
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of 400 mg albendazole and either 9‐ or 18 mg ivermectin
Study: 36540062
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg albendazole (control)
Study: 33822134
Drug: Epirubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin and cyclophosphamide followed by weekly paclitaxel (EC-wP)
Study: 33822134
Drug: Epirubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin and paclitaxel followed by weekly paclitaxel (EP-wP)
Study: 33347874
Drug: Active food
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active food preparation (making a wrap)
Study: 33347874
Drug: Passive video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive video preparation (watching video of researcher making a wrap)
Study: 32450917
Drug: Intravenous Plasma-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Plasma-Lyte 148 (Plasmalyte)
Study: 34799534
Drug: Duodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duodenal infusion of capsaicin
Study: 34640398
Drug: Caffeine 9
Normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 9 mg/kg (CAF-9)
Study: 34640398
Drug: Caffeine 12
Normalized name: caffeine 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 12 mg/kg (CAF-12)
Study: 32293514
Drug: PROUD intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PROUD intervention for increasing medication treatment of opioid use disorders (OUDs)
Study: 35063963
Drug: Levosimendan (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (12.5 mg single dose after induction of anaesthesia)
Study: 35063963
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single dose after induction of anaesthesia)
Study: 35604744
Drug: OROS‐MPH (osmotic‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS‐MPH (osmotic‐release oral system methylphenidate)
Study: 33935094
Drug: B-vitamins (folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-vitamins (folic acid 0.8 mg, vitamin B12 0.5 mg, vitamin B6 20 mg)
Study: 35896694
Drug: QL1206 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL1206 (60 mg subcutaneously every 6 months)
Study: 34670396
Drug: Genotype-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided therapy
Study: 34496270
Drug: No injections
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injections (control group)
Study: 33390325
Drug: EP0057 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP0057 (15 mg/m2 Q2W) plus paclitaxel (80 mg/m2, 3 weeks on/1 week off)
Study: 34030873
Drug: Perioperative Low-Dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perioperative Low-Dose Dexmedetomidine
Study: 32193269
Drug: self-help control
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: self-help control treatment
Study: 32560735
Drug: General information
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: General information about the correct use of complex dosage forms (Control)
Study: 33630272
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) therapy
Study: 34450619
Drug: Molnupiravir 300
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Molnupiravir 300 mg
Study: 34450619
Drug: Molnupiravir 600
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Molnupiravir 600 mg
Study: 34450619
Drug: Molnupiravir 800
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Molnupiravir 800 mg
Study: 34746976
Drug: Therapist-assisted internet-delivered
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-assisted internet-delivered cognitive behaviour therapy program
Study: 32219761
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid arm, receiving two 330 mg omega-3 fatty acid capsules daily and placebo (for vitamin D3) weekly
Study: 32219761
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D arm, receiving a 50,000 IU vitamin D3 soft gel weekly and two placebos (for omega-3 fatty acids) daily
Study: 32219761
Drug: Co-supplementation arm,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-supplementation arm, receiving a 50,000 IU vitamin D3 soft gel weekly and two 330 mg omega-3 fatty acids capsules daily for 8 weeks
Study: 35715803
Drug: GMZ2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMZ2 vaccine (two formulations: aluminum Alhydrogel and CAF01)
Study: 36898233
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg/day for 1 year
Study: 35178136
Drug: Physiotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy group (PT) received ELF EMF and LED therapy in addition to Paracetamol and NSAID-ibuprofen.
Study: 35178136
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) received Paracetamol and NSAID-ibuprofen only.
Study: 34162641
Drug: Internet-assisted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-assisted cognitive behavioural therapy (ICBT) with telephone coaching
Study: 32108355
Drug: rhIGF-1 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIGF-1 therapy
Study: 32108355
Drug: Control (glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (glucocorticoid therapy only)
Study: 35275249
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 I.U.)
Study: 34445035
Drug: 3 g·day−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g·day−1 NZBC extract
Study: 33346375
Drug: Olmesartan/rosuvastatin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/rosuvastatin fixed-dose combination (FDC)
Study: 33346375
Drug: Usual regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual regimen (separate angiotensin receptor blockers and statins)
Study: 35978350
Drug: Dengyinnaotong Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengyinnaotong Capsule plus routine basic treatment
Study: 35978350
Drug: Routine basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine basic treatment
Study: 34376218
Drug: No beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blocker therapy (Control)
Study: 34912120
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus trastuzumab and chemotherapy
Study: 34339669
Drug: Patient‐controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient‐controlled intravenous analgesia with sufentanil
Study: 34249145
Drug: Sufentanil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil + Lidocaine (S + L)
Study: 34155966
Drug: Cobalt sulfate
Normalized name: cobalt sulfate
DrugBank: Cobalt (DB14574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobalt sulfate at 0.11 mg Co/kg dry matter (DM)
Study: 34155966
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid at 7.2 mg/kg DM
Study: 34155966
Drug: Cobalt sulfate
Normalized name: cobalt sulfate
DrugBank: Cobalt (DB14574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobalt sulfate at 0.11 mg Co/kg DM
Study: 35999257
Drug: NewU (uniform
Approvals — FDA: no, EMA: no, PMDA: no
Description: NewU (uniform with a new applied fabric treatment)
Study: 33462831
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pembrolizumab every 3 weeks
Study: 33462831
Drug: Randomized dose
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized dose comparison studies (KN001 B2 and D)
Study: 35641211
Drug: Ponatinib 45
Normalized name: PONATinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 45 mg
Study: 35641211
Drug: Ponatinib 30
Normalized name: PONATinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 30 mg
Study: 35641211
Drug: Ponatinib 15
Normalized name: PONATinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 15 mg
Study: 35641211
Drug: Ponatinib 45/15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 45/15 mg
Study: 32716706
Drug: On-time denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: On-time denosumab dosing (within 4 weeks after the recommended date)
Study: 32716706
Drug: Short delay
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short delay denosumab dosing (delay by 4 to 16 weeks)
Study: 32716706
Drug: Long delay
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long delay denosumab dosing (delay by more than 16 weeks)
Study: 38800822
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg triamcinolone
Study: 38800822
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone
Study: 35318777
Drug: Colonic gas
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonic gas filling (720 mL)
Study: 34427115
Drug: Dostarlimab (Jemperli),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dostarlimab (Jemperli), administered intravenously